TransCode Therapeutics, Inc. Stock Analysis & AI Score
TransCode Therapeutics, Inc. (RNAZ) has an ST Score of 42.2 (C), driven by its Growth (A+) and held back by its Momentum (D-). Analysts rate it Buy.
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
TransCode Therapeutics, Inc. (RNAZ) has an ST Score of 42.2 (C), driven by its Growth (A+) and held back by its Momentum (D-). Analysts rate it Buy.
- Strongest
- GrowthA+
- Weakest
- MomentumD-
All factor grades
- GrowthA+
- ProfitabilityB
- ValuationC+
- Financial StrengthC
- MomentumD-
- Piotroski0/9
Contact
RNAZ stock: frequently asked questions
What is RNAZ's ST Score?
TransCode Therapeutics, Inc. (RNAZ) has an ST Score of 42.2 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RNAZ a buy, hold, or sell?
Analysts rate RNAZ a Buy. Our ST Score grades it C (42.2/100). The ST Score is a data-driven signal, not a recommendation.
What are RNAZ's factor grades?
Valuation C+, Profitability B, Financial Strength C, Momentum D-, Growth A+.
What is RNAZ's valuation grade?
TransCode Therapeutics, Inc. (RNAZ) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RNAZ's growth grade?
TransCode Therapeutics, Inc. (RNAZ) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RNAZ's profitability grade?
TransCode Therapeutics, Inc. (RNAZ) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RNAZ's financial strength grade?
TransCode Therapeutics, Inc. (RNAZ) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is RNAZ's Piotroski score?
TransCode Therapeutics, Inc. (RNAZ) has a Piotroski F-Score of 0 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.